Current lipid management and low cholesterol goal attainment in common daily practice in Spain: The REALITY study

PharmacoEconomics

Volumn 22, Issue SUPPL. 3, 2004, Pages 1-12

  Garcia Ruiz F J ^a   Marin Ibanez A ^b   Perez Jimenez F ^c   Pinto X ^d   Nocea, G ^e   Ahumada, C ^f   Alemao, Evo ^g   Yin, D ^g  

^a Las Águilas Health Centre   (Spain)

^b CS San José Norte y Centro   (Spain)

^c Infectious Diseases Section   (Spain)

^d Hospitals Generals Vall d'Hebron   (Spain)

^e MSD   (Spain)

^f Health Economics Department   (Spain)

^g MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; RESIN; SIMVASTATIN; STATIN;

ADULT; AGED; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; COHORT ANALYSIS; CORONARY RISK; DATA ANALYSIS; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SPAIN;

EID: 8344222705     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200422003-00002     Document Type: Review

References (32)

1. World Health Organization. World health report 2003 [online]. Available from URL: http://www.who.int/whr/2003/en/ [Accessed 2004 Feb 10]
2. Instituto Nacional de Estadística. Defunciones según la causa de muerte 2001 [online]. Available from URL: http://www.ine.es [Accessed 2004 Feb 10].
3. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease: the Framingham study. Ann Intern Med 1971; 74: 1-12
4. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. JAMA 1982; 248: 1465-77
5. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 334: 1383-9
6. Cholesterol and Recurrent Events (CARE) Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9
7. The LIPID Study Group. Prevention of cardiovascular events with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57
8. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7
9. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-22
10. National Heart, Lung, and Blood Institute. Third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) full report (2002) [online]. Available from URL: http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3_rpt.pdf [Accessed 2004 Feb 10]
11. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur J Cardiovasc Prev Rehab 2003; 10 Suppl. 1: S1-S78
12. Ministerio de Sanidad y Consumo. Secretaría General de Sanidad; Agencia de Calidad del Sistema Nacional de Salud 2003 [online]. Available from URL: http://www.msc.es/ planesIntegrales/PICI/pdf/cardiopatia.pdf [Accessed 2004 Feb 10]
13. PROVE-IT Study Group. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350(15): 1495-504
14. de Velasco JA, Cosín J, López JL, et al. La prevención secundaria del infarto de miocardio en España: Estudio PREVESE. Rev Esp Cardiol 1997; 50: 406-15
15. de Velasco JA, Cosín J, López JL, et al. New data on secondary prevention of myocardial infarction in Spain. Results of the PREVESE II Study. Rev Esp Cardiol 2002; 55: 801-9
16. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357: 995-1001
17. McBride P, Schrott H, Plane M, et al. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med 1998; 158: 1238-44
18. Stafford R, Blumenthal D, Pasternak R. Variations in cholesterol management practices of US physicians. J Am Coll Cardiol 1997; 29: 139-46
19. Frolklis JP, Zyzanski SJ, Schwanz JM, Sushan PS. Physician non-compliance with the National Cholesterol Education Program (NCEP - APII) guidelines. Circulation 1998; 98(9): 851-5
20. Cohen M, Byrne M, Levine B, et al. Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease. Circulation 1991; 83: 1294-304
21. EUROASPIRE Study Group. A European Society of Cardiology survey on secondary prevention of coronary heart disease: principal results. Eur Heart J 1997; 18: 1569-82
22. Shepherd J, Alcalde V, Befort P-A, for the HELP Study Group. International comparison of awareness and attitudes towards coronary risk factor reduction: the HELP study. J Cardiovasc Risk 1997; 4: 373-84
23. Merino Romero J, Gutiérrez Jodas J, López Luque C. Análisis de la prescripción de hipolipidemiantes en un centro de Atención Primaria. SEMERGEN 2002; 28: 127-30
24. Grupo de Investigación del estudio ELIPSE. Prevención secundaria de la cardiopatía isquémica en la provincia de Ciudad Real: efectividad de la terapéutica hipolipemiante en atención primaria. Med Clin (Barc) 2000; 115: 321-5
25. Martínez AA, Aguilar MJ, Rabadán M, et al. Prevención secundaria de cardiopatia isquémica a nivel lipídico en Atención Primaria Aragón. Estudio PRECIAR 1. Rev Esp Salud Pública 2001; 75: 143-50
26. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Coronary disease risk profiles. Am Heart J 1991; 121: 293-8
27. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101(2): 207-13
28. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo controlled trial. Lancet 2002; 360: 7-22
29. de Velasco JA, Llargués E, Fitó R, et al. Prevalencia de los factores de riesgo y tratamiento farmacológico al alta hospitalaria en el paciente coronario: resultados de u registro multicéntrico nacional (Programa 3C). Rev Esp Cardiol 2001; 54: 159-68
30. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. REVERSAL investigators. JAMA 2004; 291(9): 1071-80
31. Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997; 80(1): 106-7
32. Gagné C, Bays HE, Weiss SR, et al. Efficiency and safety of eztimibe added to on-going statin therapy for treatment of patients with primary hypercholesterolemia Am J Cardiol 2002; 90: 1084-1091